Clinical Neurotoxicology

Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, Fourth Edition

Volumn , Issue , 2007, Pages 191-221

  Akhtar, Jawaid ^a,b   Rittenberger, Jon C ^c   Beuhler, Michael ^d,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960795610     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0693-4.50015-3     Document Type: Chapter

References (185)

1. ER Kandel, JH Schwartz and TM Jessel (Eds) (1991) Principles of Neural Science 3rd ed. New York: Elsevier Science
2. TT Hoffman and P Taylor (2001) Neurotransmission: the autonomic and somatic motor nervous systems. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 115-153.
3. BB Hoffman (2001) Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 1215-1268.
4. HR Bourne, DA Sanders and F McCormick (1991) The GTPase superfamily: conserved structure and molecular mechanism. Nature 349 117-129.
5. TM Palmer and GL Stiles (1995) Adenosine receptor. Neuropharmacology 34 683-694.
6. M Clark and RM Post (1989) Carbamazepine, but not caffeine, is highly selective for adenosine A1 binding sites. Eur J Pharmacol 164 399-401.
7. FL Eldridge, D Paydarfar, C Scott, et al. (1989) Role of endogenous adenosine in recurrent generalized seizures. Exp Neurol 103 179-185.
8. MW Shannon and TJ Maher (1994) Anticonvulsant effects of intracerebro-ventricular adenosine in theophylline-induced seizures. Vet Hum Toxicol 36 350.
9. KV Blake, KL Massey, L Hendes, et al. (1988) Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 17 1024-1028.
10. JW Phyllis and MH O'Regan (1988) The role of adenosine in the central actions of the benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 12 389-404.
11. AB Mackenzie, A Suprenant and AB North (1999) Functional and molecular diversity of purinergic ion channel receptors. Ann NY Acad Sci 868 716-729.
12. PB Molinoff and J Axelrod (1971) Biochemistry of catecholamines. Annu Rev Biochem 40 465-500.
13. MG Caron and RJ Lefkowitz (1993) Catecholamines receptors: structure, function, and regulation. Recent Prog Horm Res 48 277.
14. RA Felder, GM Eisner and PA Jose (2000) D1 dopamine receptor signaling defect in spontaneous hypertension. Acta Physiol Scand 68 245-250.
15. DS Hartman and O Civelli (1996) Molecular attributes of dopamine receptors: new potential for antipsychotic drug development. Ann Med 28 211-219.
16. MB Murphy, C Murray and GD Shorten (2001) Drug therapy: fenoldopam—a selective peripheral dopamine-receptor agonist for the treatment of severe hypertension. N Engl J Med 345 1548-1557.
17. I Mena (1977) Manganese poisoning. PJ Vinken, GW Bruyn (Eds) Handbook of Clinical Neurology 21 New York: Elsevier Science 821-823.
18. MD Ginsberg (1980) Carbon monoxide. PS Spencer, HH Schaumburg (Eds) Experimental and Clinical Neurotoxicology Baltimore: William & Wilkins 374-394.
19. SM Aquilonius, H Asmark, P Enoksson, et al. (1978) Computerised tomography in severe methanol intoxication. BMJ 2 929.
20. FS He (1987) Extrapyramidal lesions induced by mildewed cane poisoning (with report of three cases). Chung Hua I Hsueh Tsa Chih 67 395-396.
21. CM Tanner and JW Langston (1990) Do environmental toxins cause Parkinson's disease? A critical review. Neurology 322 1781-1787.
22. MA Granner and GF Wooten (1991) Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome. Semin Neurol 11 228-335.
23. DEA Intelligence Division. (2002, October). Trippin' on tryptamines: the emergence of foxy and AMT as drugs of abuse. Accessed January 6, 2004, at http://www.usdoj.gov/dea/pubs/intel/02052/02052p.html.
24. E Sanders-Bush and SE Mayer (2001) 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 269-290.
25. KC Mill (1995) Serotonin syndrome. Am Fam Med 52 1475-1482.
26. T Reisine (1995) Opiate receptors. Neuropharmacology 34 463-472.
27. HB Gutstein and H Akil (2001) Opioid analgesics. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 569-619.
28. RF Kaiko, KM Foley, PY Grabinski, et al. (1983) Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 13 180-185.
29. JL Galzi and JP Changeux (1995) Molecular organization and regulations. Neuropharmacology 34 563-582.
30. JH Brown and P Taylor (2001) Muscarinic receptor agonists and antagonists. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 155-173.
31. BJ Benson, D Tolo and M McIntire (1992) Is the intermediate syndrome in organophosphate poisoning the result of insufficient oxime therapy? J Toxicol Clin Toxicol 30 347-349.
32. LM Haddad (1992) Organophosphate poisoning: intermediate syndrome? J Toxicol Clin Toxicol 30 331-332.
33. CS Kitchens and LH Van Mierop (1987) Envenomation by the eastern coral snake (Micrurus fulvius). JAMA 258 1615-1618.
34. A Rauber (1983–84) Black widow spider bites. J Toxicol Clin Toxicol 21 473.
35. GM Nicholson and A Graudins (2002) Spiders of medical importance in the Asia-Pacific: Atracogoxin, latrotoxin and related spider neurotoxins. Clin Exp Pharmacol Physiol 29 785-794.
36. JC Kincaid (1990) Tick bite paralysis. Semin Neurol 10 32-34.
37. P Taylor (2001) Agents acting at the neuromuscular junction and autonomic ganglia. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 193-213.
38. LB Hough (1987) Cellular localization and possible functions for brain histamine: recent progress. Prof Neurobiol 30 469-505.
39. NJ Brown and LJ Roberts II (2001) Histamine, bradykinin, and their antagonists. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 645-667.
40. JP Pin and R Duvoisin (1995) The metabotrophic glutamate receptors: structure and functions. Neuropharmacology 34 1219-1237.
41. B Bettler and C Mulle (1995) AMPA and kainate receptors. Neuropharmacology 34 123-139.
42. H Mori and M Mishina (1995) Structure and function of the NMDA receptor channel. Neuropharmacology 34 1219-1237.
43. NW Kleckner and R Dingledine (1988) Requirements for glycine in activation of NMDA receptors expressed in Xenopus oocyte. Science 241 835-837.
44. K Williams, C Romano, MA Dichter, et al. (1991) Modulation of the NMDA receptor by polyamines. Life Sci 48 469-498.
45. FF Weight, DM Lovinger, G White, et al. (1990) Alcohol and anaesthetic actions on excitatory amino acid-activated ion channels. Ann N Y Acad Sci 625 97-107.
46. PL Hoffman, KA Grant, LD Snell, et al. (1992) NMDA receptors: role in ethanol withdrawal seizures. Ann N Y Acad Sci 654 52-60.
47. JW Olney (1990) Excitatory amino acids and neuropsychiatric disorders. Ann Rev Pharmacol Toxicol 30 47-71.
48. TM Perl, L Bedard, T Kosatsky, et al. (1990) An outbreak of toxic encephalopathy caused by eating mussels contaminated with domoic acid. N Engl J Med 322 1775-1780.
49. H Luddens, ER Korpi and PH Seeburg (1995) GABAA/benzodiazepine receptor heterogeneity: neurophysiological implications. Neuropharmacology 34 245-254.
50. P Krogsgaard-Larsen, L Brehm and K Schaumburg (1981) Muscimol, a psychoactive constituent of Amanita muscaria, as a medicinal chemical model structure. Acta Chem Scand [B] 35 311-324.
51. H Mohler and T Okada (1977) Benzodiazepine receptor: demonstration in the central nervous system. Science 198 849-851.
52. ER Korpi, MJ Mattila, W Wisden and H Luddens (1997) GABA-A receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med 29 275-282.
53. MD Majewska, NL Harrison, RD Schwartz, et al. (1986) Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 232 1004-1007.
54. AM Allan and RA Harris (1986) Anesthetic and convulsant barbiturates alter γ-aminobutyric acid-stimulated chloride flux across brain membranes. J Pharmacol Exp Ther 238 763-768.
55. PD Suzdak, RD Schwartz, P Skolnick, et al. (1986) Ethanol stimulates γ-aminobutyric acid receptor-mediated chloride transport in rat brain synaptoneurosomes. Proc Natl Acad Sci U S A 83 4071-4075.
56. HL William, MS Killah, EH Jenny, et al. (1951) Convulsant effects of isoniazid. JAMA 152 1317-1321.
57. RE Gosselin, RP Smith and HC Hodge (1984) Clinical Toxicology of Commercial Products 5th ed. Baltimore: Williams & Wilkins
58. SC Lummis, SD Buckinham, JJ Rauh, et al. (1990) Blocking actions of heptachlor at an insect central nervous system GABA receptor. Proc R Soc Lond Biol Sci 240 97-106.
59. N Ogata (1990) Pharmacology and physiology of GABAB receptors. Gen Pharmacol 21 395-402.
60. D Langosch, CM Becker and H Betz (1990) The inhibitory glycine receptor: a ligand-gated chloride channel of the central nervous system. Eur J Biochem 194 1-8.
61. HH Schaumberg, PS Spencer and PK Thomas (Eds) (1983) Disorder of Peripheral Nerves Philadelphia: F. A. Davis
62. P LeWitt (1980) The neurotoxicity of the rat poison vacor. N Engl J Med 302 73-77.
63. PS Spencer, HH Schaumberg, M Sabri, et al. (1980) The enlarging view of hexacarbon neurotoxicity. Crit Rev Toxicol 7 279-356.
64. AJ Windebank and MD Blexrud (1989) Residual ethylene oxide in hollow fiber hemodialysis units is neurotoxic in vitro. Ann Neurol 26 63-68.
65. Y Murai and Y Kuroiwa (1971) Peripheral neuropathy in chlorobiphenyl poisoning. Neurology 21 1173-1176.
66. J Delay, P Pichot, T Lemperiere, et al. (1960) Un neuroleptique majeur nonphenothiazine et non-reserpinique, l'haloperidol, dans le traitement des psychoses. Ann Med Psychol 118 145-152.
67. SN Caroff and SC Mann (1993) Neuroleptic malignant syndrome. Med Clin North Am 77(1), 185-202.
68. PE Keck, HG Pope and SL McElroy (1991) Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 148 880-882.
69. AJ Gelenberg, B Bellinghansen, JD Wojcik, et al. (1988) A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am J Psychiatry 145 517-518.
70. PE Keck, J Sebastianelli, HG Pope, et al. (1989) Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. J Clin Psychiatry 50 352-355.
71. DK Farver (2003) Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2(1), 22-35.
72. FL Karagianis, LC Phillips, KP Hogan and KK LeDrew (1999) Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 33 623-630.
73. JH Friedman, SS Feinberg and RG Feldman (1985) A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 254(19), 2792-2795.
74. H Hermesh, P Sirota and J Eviatar (1989) Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine. Biol Psychiatry 25 962-965.
75. E Friedman and S Gershon (1973) Effect of lithium on brain dopamine. Nature 243 520-521.
76. G Spring and M Frankel (1981) New data on lithium and haloperidol incompatibility. Am J Psychiatry 138(6), 818-821.
77. JM Davis, SN Caroff and SC Mann (2000) Treatment of neuroleptic malignant syndrome. Psychiatr Ann 30(5), 325-331.
78. BT Carroll and RE Taylor (1997) The nondichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 17(3), 235-236.
79. S Korsgaard, J Gerlach and E Christensson (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118 245-252.
80. CJ Carter and CJ Pycock (1977) Possible importance of 5-hydroxytryptamine in neuroleptic induced catalepsy in rats [proceedings]. Br J Pharmacol 60(2), 267P-268P.
81. S Kapur and G Remington (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153(4), 466-476.
82. M Halman and DS Goldbloom (1990) Fluoxetine and neuroleptic malignant syndrome. Biol Psychiatry 28 518-521.
83. CF Caley (1997) Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 31 1481-1489.
84. G Addonizio, VL Susman and SD Roth (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22 1004-1020.
85. V Totten, E Hirschenstein and P Hew (1994) Neuroleptic malignant syndrome presenting without initial fever: a case report. J Emerg Med 12(1), 43-47.
86. C Taylor, G Rogers, C Goodman, et al. (1987) Hematologic, iron-related, and acute-phase protein responses to sustained strenuous exercise. J Appl Physiol 62(2), 464-469.
87. PI Rosebush and MF Mazurek (1991) Serum iron and neuroleptic malignant syndrome. Lancet 338 149-150.
88. PN Van Harten and CJF Kemperman (1991) Organic amnestic disorder: a long-term sequel after neuroleptic malignant syndrome. Biol Psychiatry 29 407-410.
89. S Caroff, SC Mann, PE Keck Jr and A Francis (2000) Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 20(2), 257-259.
90. RS Mitchell (1955) Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Intern Med 42 417-424.
91. JA Oates and A Sjoerdsma (1960) Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology 10 1076-1078.
92. DG Grahame-Smith (1971) Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 18 1055-1066.
93. TR Insel, BF Roy, RM Cohen, et al. (1982) Possible development of the serotonin syndrome in man. Am J Psychol 139 954-955.
94. PK Gillman (1999) The serotonin syndrome and its treatment. J Psychopharmacol 13 100-109.
95. K Nisijima, K Shioda, T Yoshino, et al. (2003) Diazepam and chlor-methiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int 43 155-164.
96. K Nisijima, T Yoshino, K Yui and S Katoh (2001) Potent serotonin (5-HT)2A receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome. Brain Res 890 23-31.
97. P Mazzola Pomietto, CS Aulakh, KM Wozniak, et al. (1995) Evidence that 1-(2,5-dimethoxy-4-iodophenol)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors. Psychopharmacology 117 193-199.
98. GJ Siegel (Eds) (1999) Basic Neurochemistry Philadelphia: Lippincott Williams & Wilkins
99. S Zerjav-Lacombe and V Dewan (2001) Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine. Ann Pharmacother 35 180-182.
100. Z Horowitz and ME Mullins (1999) Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. Pediatr Emerg Care 15(5), 325-327.
101. GK Isbister, SJ Bowe, A Dawson and IM Whyte (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 42 277-285.
102. M Tatsumi, K Groshan, RD Blakely and E Richelson (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Euro J Pharmacol 340 249-258.
103. IM Whyte, AH Dawson and NA Buckley (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 96 369-374.
104. PK Gillman (1998) Serotonin syndrome: history and risk. Fundam Clin Pharmacol 12 482-491.
105. Gillman K: Serotonin toxicity. Accessed January 15, 2005, at http://www.psychotropical.com/SerotoninToxicity.doc.
106. TA Bamigbade, C Davidson, RM Langford and JA Stamford (1997) Actions of tramadol, its enantiomers and principle metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth 79 352-356.
107. TR Brodribb, M Downey and PJ Gilbar (1994) Efficacy and adverse effects of moclobemide. Lancet 343 475.
108. GL Zornberg, JA Bodkin and BM Cohen (1991) Severe adverse interaction between pethidine and selegiline. Lancet 337 246.
109. NP Hinds, CE Hiller and CM Wiles (2000) Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism. J Neurol 247 811.
110. E Francis and F Harchelroad (1996) LSD/fluoxetine-induced serotonin syndrome. J Toxicol Clin Toxicol 34(5), 560.
111. CA Marsden and DJ Heal (Eds) (1992) Central Serotonin Receptors and Psychotropic Drugs Oxford: Blackwell Scientific
112. ED Brush, SB Bird and EW Boyer (2004) Monoamine oxidase inhibitor poisoning resulting from Internet misinformation on illicit substances. J Toxicol Clin Toxicol 42(2), 191-195.
113. JG Hardman and LE Limbird (Eds) (1996) Goodman & Gillman's The Pharmacological Basis of Therapeutics 9th ed. New York: McGraw-Hill
114. L John, MM Perreault, T Tao and PG Blew (1997) Serotonin syndrome associated with nefazodone and paroxetine. Ann Emerg Med 29(2), 287-289.
115. M Baetz and D Malcolm (1995) Serotonin syndrome from fluvoxamine and buspirone. Can J Psychiatry 40(7), 428-429.
116. NT Mathew, GE Tietjen and C Lucker (1996) Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 16 323-327.
117. SB Turkel, JG Nadala and MZ Wincor (2001) Possible serotonin syndrome in association with 5-HT3 antagonist agents. Psychosomatics 42(3), 258-260.
118. R Sandyk (1986) L-Dopa induced “serotonin syndrome” in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 6(3), 194.
119. MJ Kuisma (1995) Fatal serotonin syndrome with trismus. Ann Emerg Med 26(1), 108.
120. KC Mills (1997) Serotonin syndrome: a clinical update. Crit Care Clin 13(4), 763-783.
121. H Sternbach (1991) The serotonin syndrome. Am J Psychiatry 148 705-813.
122. MA Denborough, JF Forster, RR Lovell, et al. (1962) Anaesthetic deaths in a family. Br J Anaesth 34 395-396.
123. JR Mickelson and CF Louis (1996) Malignant hyperthermia: excitation-contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Physiol Rev 76(2), 537-592.
124. TE Nelson and EH Flewellen (1983) The malignant hyperthermia syndrome. N Engl J Med 309(7), 416-418.
125. BA Britt and W Kalow (1970) Malignant hyperthermia: a statistical review. Can Anaesth Soc J 17(4), 293-315.
126. JE Lane, AG Brooks, MS Logan, et al. (2000) An unusual case of malignant hyperthermia during desflurane anesthesia in an African-American patient. Anesth Analg 91 1032-1034.
127. OM Jardon (1982) Physiologic stress, heat stroke, malignant hyperthermia—a perspective. Milit Med 147 8-14.
128. D Bendahan, G Kozak-Ribbens, S Confort-Gouny, et al. (2001) A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg 93 683-689.
129. F Wappler, M Fiege, M Steinfath, et al. (2001) Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 94 95-100.
130. F Wappler, M Fiege, M Antz and J Schulte am Esch (2000) Hemodynamic and metabolic alterations in response to graded exercise in a patient susceptible to malignant hyperthermia. Anesthesiology 92 268-272.
131. JR Tobin, DR Jason, VR Challa, et al. (2001) Malignant hyperthermia and apparent heat stroke. JAMA 286(2), 168-169.
132. D Bendahan, G Kozak-Ribbens, L Rodet, et al. (1998) 31Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies in patients with malignant hyperthermia: application of diagnosis. Anesthesiology 88(1), 96-107.
133. JR Lopez, J Contreras, N Linares and PD Allen (2000) Hypersensitivity of malignant hyperthermia-susceptible swine skeletal muscle to caffeine is mediated by high resting myoplasmic [Ca2+]. Anesthesiology 92 1799-1806.
134. A Standec and G Stefano (1984) Cyclic AMP in normal and malignant hyperpyrexia susceptible individuals following exercise. Br J Anaesth 56 1243-1246.
135. JE Fletcher, SJ Wieland, SM Karan, et al. (1997) Sodium channel in human malignant hyperthermia. Anesthesiology 86(5), 1023-1032.
136. SP Ball and KJ Johnson (1993) The genetics of malignant hyperthermia. J Med Genet 30(2), 89-93.
137. RJL Gurrera (2002) Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin Neuropharmacol 25(4), 183-193.
138. C Lambert, Y Blanloeil, RK Horber, et al. (1994) Malignant hyperthermia in a patient with hypokalemic periodic paralysis. Anesth Analg 79 1012-1014.
139. F Wappler, J Scholz, V von Richthofen, et al. (1997) Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene. Acta Anesthesiol Scand 41 1312.
140. F Wappler, J Scholz, S Oppermann, et al. (1997) Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia susceptible patients. J Clin Anesth 9 306-311.
141. F Wappler, M Fiege and J Schulte am Esch (2001) Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth 87(5), 794-798.
142. F Wappler, N Roewer, A Kochling, et al. (1996) Effects of the serotonin 2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients. Anesthesiology 84(6), 1280-1287.
143. A Richter, J Scholz, W Loscher, et al. (1996) Effects of the 5-HT2 receptor antagonist ritanserin on halothane-induced increase of inositol phosphates in porcine malignant hyperthermia. Arch Pharmacol 354 593-597.
144. W Löscher, C Gerdes and A Richter (1994) Lack of prophylactic or therapeutic efficacy of 5-HT2A receptor antagonists in halothane induced porcine malignant hyperthermia. Arch Pharmacol 350 365-374.
145. F Wappler, J Scholz, M Fiege, et al. (1999) 5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients. Naunyn Schmiedebergs Arch Pharmacol 360 376-381.
146. H Hermesh, D Aizenberg, M Lapidot and H Munitz (1988) Risk of malignant hyperthermia among patients with neuroleptic malignant syndrome and their families. Am J Psychiatry 145(11), 1431-1434.
147. GC Allen and CL Brubaker (1998) Human malignant hyperthermia associated with desflurane anesthesia. Anesth Analg 86(6), 1328-1331.
148. M Fiege, F Wappler, R Weisshorn, et al. (2003) In vitro and in vivo effects of the phosphodiesterase-iii inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology 98 944-949.
149. FC Riess, M Fiege, S Moshar, et al. (2001) Rhabdomyolysis following cardiopulmonary bypass and treatment with enoximone in a patient susceptible to malignant hyperthermia. Anesthesiology 94 355-357.
150. M Fiege, F Wappler, J Scholz, et al. (2000) Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients. J Clin Anesth 12 123-128.
151. AJ McKenzie, KG Couchman and N Pollock (1992) Propofol is a “safe” anesthetic agent in malignant hyperthermia susceptible patients. Anaesth Intensive Care 20(2), 165-168.
152. L Fierobe, Y Nivoche, J Mantz, et al. (1998) Perioperative severe rhabdomyolysis revealing susceptibility to malignant hyperthermia. Anesthesiology 88(1), 263-265.
153. T Harwood and TE Nelson (1998) Massive postoperative rhabdomyolysis after uneventful surgery: a case report of subclinical malignant hyperthermia. Anesthesiology 88(1), 265-268.
154. CW Hoenemann, TB Halene-Holtgraeve, M Booke, et al. (2003) Delayed onset of malignant hyperthermia in desflurane anesthesia. Anesth Analg 96 165-167.
155. ER Wohlfeil, HJ Woehlck and ND McElroy (1998) Malignant hyperthermia triggered coincidentally after reversal of neuromuscular blockade in a patient from the Hmong. People of Laos 88(6), 1667-1668.
156. G Islander and ER Twetman (1999) Comparison between the European and North American protocols for diagnosis of malignant hyperthermia susceptibility in humans. Anesth Analg 88(5), 1155-1160.
157. GC Allen, MG Larach and AR Kunselman (1998) The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American malignant hyperthermia registry. Anesthesiology 88(3), 579-588.
158. H Ørding, G Islander, D Bendixen and E Ranklev-Twetman (2000) Between-center variability of results of the in vitro contracture test for malignant hyperthermia susceptibility. Anesth Analg 91(2), 452-457.
159. S Caroff, H Rosenberg and JC Gerber (1983) Neuroleptic malignant syndrome and malignant hyperthermia. Lancet 1(8318), 244.
160. R Sangal and R Dimitrijevic (1985) Neuroleptic malignant syndrome successful treatment with pancuronium. JAMA 254(19), 2795-2796.
161. A Francis, M Koch, S Chandragiri, et al. (2000) Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectrum 5 54-57.
162. DJ Wedel, JG Quinlan and PA Iaizzo (1995) Clinical effects of intravenously administered dantrolene. Mayo Clin Proc 70 241-246.
163. JT Amsterdam, SA Syverud, WJ Barker, et al. (1986) Dantrolene sodium for treatment of heatstroke victims: lack of efficacy in a canine model. Am J Emerg Med 4 399-405.
164. P Sakkas, JM Davis, J Hua, et al. (1991) Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr Ann 21 157-164.
165. P Sakkas, JM Davis, PG Janicak, et al. (1991) Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 27 381-384.
166. CS Hutt, SR Snider and S Fahn (1977) Interaction between bromocriptine and levodopa. Neurology 27 505-510.
167. MM McCarron, ML Boettger and JJ Peck (1982) A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatry 43(9), 381-382.
168. J Kornhuber and M Weller (1997) Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy. Biol Psychiatry 41 135-144.
169. K Nisijima and T Ishiguro (1999) Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. J ECT 15(2), 158-163.
170. A Graudins, A Stearman and B Chan (1998) Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 16(4), 615-619.
171. PK Gillman (1997) Serotonin syndrome treated with chlorpromazine. J Clin Psychopharmacol 17 128-129.
172. JL Cano-Munoz, ML Montejo-Iglesias, RM Yanez-Saez and IM Galvez-Borrero (1995) Possible serotonin syndrome following the combined administration of clomipramine and alprazolam. J Clin Psychiatry 56(3), 122.
173. BH Guze and LR Baxter (1986) The serotonin syndrome: case responsive to propranolol. J Clin Psychopharmacol 6(2), 119-120.
174. MJAJM Hoes (1996) Mirtazapine as treatment for serotonin syndrome. Pharmacopsychiatry 29 81.
175. T de Boer (1996) The pharmacologic profile of mirtazapine. J Clin Psychiatry 57 19-25.
176. TM Brown (1996) Nitroglycerine in the treatment of the serotonin syndrome. Ann Pharmacother 30 191.
177. SS Kline, LS Mauro, DM Scala-Barnett and D Zick (1989) Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 8 510-514.
178. K Nisijima, K Shioda, T Yoshino, et al. (2004) Memantine, an NMDA antagonist, prevents the development of hyperthermia in an animal model for serotonin syndrome. Pharmacopsychiatry 37 57-62.
179. S Hamilton and K Malone (2000) Serotonin syndrome during treatment with paroxetine and risperidone. J Clin Psychopharmacol 20(1), 103-105.
180. K Nisijima and T Ishiguro (1993) Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study. Biol Psychiatry 33 45-48.
181. P Kolecki (1997) Venlafaxine induced serotonin syndrome occurring after abstinence from phenelzine for more than two weeks. J Toxicol Clin Toxicol 35 211-212.
182. ME Kolb, ML Horne and R Martz (1982) Dantrolene in human malignant hyperthermia: a multicenter study. Anesthesiology 56 254-262.
183. A Ward, MO Chaffman and ME Sorkin (1986) Dantrolene, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update on its use in muscle spasticity. Drugs 32 130-168.
184. T Nelson, M Lin, G Zapata-Sudo and RT Sudo (1996) Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel: clinical implications. Anesthesiology 84(6), 1368-1379.
185. AC San Juan, KC Wong and JD Port (1988) Hyperkalemia after dantrolene and verapamil-dantrolene administration in dogs. Anesth Analg 67 759-762.